InhaleRx (ASX:IRX) Cash Receipts from Operating Activities : A$0.76 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Cash Receipts from Operating Activities?

InhaleRx's Cash Receipts from Operating Activities for the six months ended in Dec. 2024 was A$0.00 Mil.

InhaleRx's Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.76 Mil.

InhaleRx Cash Receipts from Operating Activities Historical Data

The historical data trend for InhaleRx's Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Cash Receipts from Operating Activities Chart

InhaleRx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Receipts from Operating Activities

Get a 7-Day Free Trial

0.09

0.13

0.44

0.76

InhaleRx Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash Receipts from Operating Activities	Get a 7-Day Free Trial												-	-	-	0.76	-

InhaleRx Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.76 Mil.

InhaleRx Cash Receipts from Operating Activities Related Terms

Thank you for viewing the detailed overview of InhaleRx's Cash Receipts from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

InhaleRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InhaleRx Ltd (ASX:IRX) » Definitions » Cash Receipts from Operating Activities

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000

Website

https://www.inhalerx.com.au

InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines